This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Teleflex (TFX) Q1 Earnings Top Estimates, Margins Decline
by Zacks Equity Research
Teleflex (TFX) reports robust improvement in revenues on balanced growth across all segments and geographies.
KLA-Tencor (KLAC) to Post Q3 Earnings: What's in the Cards?
by Zacks Equity Research
KLA-Tencor's (KLAC) fiscal third-quarter earnings are likely to benefit from solid product portfolio. However, memory weakness and intensifying competition may impact its results.
Teleflex (TFX) Surpasses Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Teleflex (TFX) delivered earnings and revenue surprises of 3.70% and 1.00%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
What's in Store for AmerisourceBergen (ABC) in Q2 Earnings?
by Zacks Equity Research
Better-than-expected performance at Pharmaceutical Distribution and World Courier and higher revenues might aid AmerisourceBergen (ABC) in Q2 earnings. However, stiff competition might be a dampener.
Will Strong Competition Hurt Fitbit's (FIT) Earnings in Q1?
by Zacks Equity Research
Fitbit's (FIT) focus on innovation, including new smartwatches, is likely to benefit first-quarter results. However, intensifying competition in the wearables market remains a major concern.
What's in the Cards for Expedia Group's (EXPE) Q1 Earnings?
by Zacks Equity Research
Strength across segments is likely to drive Expedia Group's (EXPE) first-quarter revenues.
Can Mass Cytometry Drive Fluidigm's (FLDM) Q1 Earnings?
by Zacks Equity Research
Better-than-expected performance at mass cytometry market and higher revenues is likely to aid Fluidigm's (FLDM) in Q1 earnings. However, sluggishness in microfluidics market remains a dampener.
DENTSPLY SIRONA (XRAY) Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Higher Consumable revenues, product innovation and focus on R&D likely to aid DENTSPLY SIRONA (XRAY) in Q1 earnings. However, contraction is gross margin might be a dampener.
Integer Holdings (ITGR) Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Better-than-expected performance at C&V and Cardiac & Neuromodulation product lines and higher revenues might aid Integer Holdings (ITGR) in Q1. But decline in non-medical sales might be a dampener.
Teleflex (TFX) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Teleflex (TFX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Thermo Fisher (TMO) to Report Q1 Earnings: What's in Store?
by Zacks Equity Research
Strong analytical instruments business, product portfolio expansion and prudent growth strategy are likely to support Thermo Fisher (TMO) in Q1. However, forex might act as a dampener.
What's in Store for Align Technology (ALGN) in Q1 Earnings?
by Zacks Equity Research
Higher Invisalign case volume, solid show by Clear Aligner segment and anticipated sturdy growth at Scanner and Service business are likely to support Align Technology (ALGN) in Q1. However, operating expenses are likely to act as dampeners.
Why Is Teleflex (TFX) Up 9.6% Since Last Earnings Report?
by Zacks Equity Research
Teleflex (TFX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
TeleFlex Announces Multiple Positive Outcomes on UroLift
by Zacks Equity Research
A study by TeleFlex (TFX) sheds light on the real-world retrospective data on 30 men suffering urinary retention treated with the UroLift System.
Teleflex (TFX) Q4 Earnings Miss Estimates, Margins Rise
by Zacks Equity Research
In Q4, Teleflex (TFX) registers strong growth in PICC, visual navigation products and EZ-IO.
Teleflex (TFX) Q4 Earnings Lag Estimates
by Zacks Equity Research
Teleflex (TFX) delivered earnings and revenue surprises of -0.36% and 0.25%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?
Teleflex (TFX) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Teleflex (TFX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Teleflex (TFX) Up 4.5% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Teleflex (TFX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Teleflex (TFX) Q3 Earnings Surpass Estimates, EPS View Up
by Zacks Equity Research
Teleflex (TFX) consistently rides high on a robust uptick in revenues, backed by stable segmental growth and solid geographical expansions.
Teleflex (TFX) Q3 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Teleflex (TFX) delivered earnings and revenue surprises of 4.56% and 0.06%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
Teleflex (TFX) Q3 Earnings Preview: What to Know Ahead of the Release
by Zacks Equity Research
Teleflex (TFX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Teleflex's Latest Essential Medical Buyout to Broaden Suite
by Zacks Equity Research
Teleflex (TFX) acquires Essential Medical to strengthen hold in the high-potential structural heart and endovascular aneurysm repair markets.
Teleflex (TFX) Q2 Earnings Top, Sales Lag, '18 View Bearish
by Zacks Equity Research
Teleflex (TFX) rides high on a strong year-over-year revenue improvement, banking on balanced segmental growth and wide geographical expansion.
Teleflex (TFX) Q2 Earnings Surpass Estimates
by Zacks Equity Research
Teleflex (TFX) delivered earnings and revenue surprises of 2.49% and -1.19%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
Should You Buy Teleflex (TFX) Ahead of Earnings?
by Zacks Equity Research
Teleflex (TFX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.